- Home
- PRPO vs EVAX Comparison
PRPO vs EVAX Comparison
Compare PRPO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- EVAX
- Stock Information
- Founded
- PRPO N/A
- EVAX 2008
- Country
- PRPO United States
- EVAX Denmark
- Employees
- PRPO N/A
- EVAX N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRPO Industrials
- EVAX Health Care
- Exchange
- PRPO Nasdaq
- EVAX Nasdaq
- Market Cap
- PRPO 22.0M
- EVAX 17.8M
- IPO Year
- PRPO N/A
- EVAX 2021
- Fundamental
- Price
- PRPO $17.55
- EVAX $2.93
- Analyst Decision
- PRPO
- EVAX Strong Buy
- Analyst Count
- PRPO 0
- EVAX 2
- Target Price
- PRPO N/A
- EVAX $10.00
- AVG Volume (30 Days)
- PRPO 16.8K
- EVAX 68.5K
- Earning Date
- PRPO 11-05-2025
- EVAX 10-30-2025
- Dividend Yield
- PRPO N/A
- EVAX N/A
- EPS Growth
- PRPO N/A
- EVAX N/A
- EPS
- PRPO N/A
- EVAX N/A
- Revenue
- PRPO $21,242,000.00
- EVAX $3,176,000.00
- Revenue This Year
- PRPO N/A
- EVAX N/A
- Revenue Next Year
- PRPO N/A
- EVAX $425.50
- P/E Ratio
- PRPO N/A
- EVAX N/A
- Revenue Growth
- PRPO 27.05
- EVAX 1042.45
- 52 Week Low
- PRPO $3.90
- EVAX $1.20
- 52 Week High
- PRPO $22.38
- EVAX $16.69
- Technical
- Relative Strength Index (RSI)
- PRPO 53.87
- EVAX 51.89
- Support Level
- PRPO $19.40
- EVAX $2.81
- Resistance Level
- PRPO $22.38
- EVAX $3.04
- Average True Range (ATR)
- PRPO 1.39
- EVAX 0.21
- MACD
- PRPO -0.01
- EVAX -0.00
- Stochastic Oscillator
- PRPO 40.33
- EVAX 68.64
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.